<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03272724</url>
  </required_header>
  <id_info>
    <org_study_id>Observatoire EI</org_study_id>
    <nct_id>NCT03272724</nct_id>
  </id_info>
  <brief_title>French National Observatory on Infective Endocarditis</brief_title>
  <acronym>ObservatoireEI</acronym>
  <official_title>French National Observatory on Infective Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bichat Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Pointe-a-Pitre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Saint André, Reims</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this observatory is to provide a national database of infective
      endocarditis, informed by all volunteer centers, using a standardized case report forms.

      Such an observatory will describe the clinical profile, microbiological, therapeutic and
      evolving of infective endocarditis (IE); analyze the risk factors for the disease and its
      prognosis factors of evolution; describe management practices; evaluate and compare in the
      real drug treatment strategies (including antibiotics) and surgical.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the clinical, biological, microbiological and laboratory describing the history of
      patients and their evolution during hospitalization for infective endocarditis will be
      obtained from physicians supporting patients and recorded in an electronic case report form.
      Will include collected clinical characteristics (site, pre-existing heart disease underlying
      symptoms, complications), biological characteristics (dosage on admission and diagnosis),
      microbiological characteristics (identifying the genus and species of the microorganism
      responsible, sensitivity to antibiotics susceptibility testing and evaluated by determination
      of minimal inhibiting concentration (MIC), exhaustive search of the rare forms of
      endocarditis uncultivated microorganisms), an analysis of the gateways based on the causative
      organism; echocardiographic characteristics (number and size of vegetations, valvular damage,
      scalable: surgery, lethality) and therapeutic characteristics (antibiotic treatment,
      surgical).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 1991</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>history of heart disease</measure>
    <time_frame>inclusion</time_frame>
    <description>status of heart valves, pre-existing heart conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>risk factors, medical history</measure>
    <time_frame>inclusion</time_frame>
    <description>associated diseases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>origin of infection</measure>
    <time_frame>period of 3 months before infective endocarditis</time_frame>
    <description>high risk procedures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>weight</measure>
    <time_frame>inclusion</time_frame>
    <description>kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>height</measure>
    <time_frame>inclusion</time_frame>
    <description>cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical symptoms</measure>
    <time_frame>inclusion</time_frame>
    <description>cardiac, peripheral and neurological symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>biological outcomes</measure>
    <time_frame>inclusion</time_frame>
    <description>blood count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>microbiological outcomes</measure>
    <time_frame>inclusion</time_frame>
    <description>identification of infecting organisms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>diagnostic imaging</measure>
    <time_frame>inclusion</time_frame>
    <description>description of tyhe imaging tests performed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antibiotic therapy</measure>
    <time_frame>from inclusion to recovery</time_frame>
    <description>antibiotic treatment: type and duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>surgical procedures</measure>
    <time_frame>from inclusion to recovery</time_frame>
    <description>description of surgical procedures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biologic collection (optional)</measure>
    <time_frame>inclusion</time_frame>
    <description>plasma and serum collection</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Infective Endocarditis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult hospitalized patients, suspected of infective endocarditis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major Patient

          -  Supported in one of the participating centers

          -  The application of diagnostic classification criteria of Duke modified by Li is
             carried out after collection of all the data at the end of the patient's
             hospitalization. Only patients meeting criteria for definite or possible endocarditis
             will be included in the analyses.

          -  Registered with the French social security system

        Exclusion Criteria:

        • Refusal of the patient to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine SELTON-SUTY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadine JUGE, PhD</last_name>
    <email>n.juge@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine SELTON-SUTY, MD</last_name>
      <email>c.suty-selton@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Selton-Suty C, Goehringer F, Venner C, Thivilier C, Huttin O, Hoen B; membres de l’Endocarditis Team du CHU de Nancy. [Complications and prognosis of infective endocarditis]. Presse Med. 2019 May;48(5):532-538. doi: 10.1016/j.lpm.2019.04.002. Epub 2019 May 2. Review. French.</citation>
    <PMID>31056233</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoen B, Elfarra M, Huttin O, Goehringer F, Venner C, Selton-Suty C; l’Endocarditis Team du CHU de Nancy. [Treatment of infectious endocarditis]. Presse Med. 2019 May;48(5):539-548. doi: 10.1016/j.lpm.2019.04.015. Epub 2019 May 18. Review. French.</citation>
    <PMID>31109766</PMID>
  </results_reference>
  <results_reference>
    <citation>N'Guyen Y, Duval X, Revest M, Saada M, Erpelding ML, Selton-Suty C, Bouchiat C, Delahaye F, Chirouze C, Alla F, Strady C, Hoen B; AEPEI study group. Time interval between infective endocarditis first symptoms and diagnosis: relationship to infective endocarditis characteristics, microorganisms and prognosis. Ann Med. 2017 Mar;49(2):117-125. doi: 10.1080/07853890.2016.1235282. Epub 2016 Nov 3.</citation>
    <PMID>27607562</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis, Bacterial</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

